Solid Biosciences (SLDB) EPS (Weighted Average and Diluted) (2020 - 2024)
Solid Biosciences (SLDB) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$1.02 as the latest value for Q4 2024.
- Quarterly EPS (Weighted Average and Diluted) fell 2.0% to -$1.02 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$3.06 through Dec 2024, up 36.78% year-over-year, with the annual reading at -$1.99 for FY2025, 34.97% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$1.02 in Q4 2024 for Solid Biosciences, down from -$0.79 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.17 in Q2 2021 to a low of -$6.17 in Q4 2020.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.82 across 5 years, with a median of -$1.15 in 2023.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 72.36% in 2022; the steepest drop was 1858.82% in 2022.
- Year by year, EPS (Weighted Average and Diluted) stood at -$6.17 in 2020, then surged by 60.13% to -$2.46 in 2021, then skyrocketed by 72.36% to -$0.68 in 2022, then plummeted by 47.06% to -$1.0 in 2023, then fell by 2.0% to -$1.02 in 2024.
- Business Quant data shows EPS (Weighted Average and Diluted) for SLDB at -$1.02 in Q4 2024, -$0.79 in Q3 2024, and -$0.61 in Q2 2024.